TGFB1 and hereditary hemorrhagic telangiectasia: One such drug, thalidomide, and its less toxic counterpart lenalidomide, have been shown to reduce nose bleeds and GI hemorrhage in HHT patients by inhibiting angiogenic factors like TGF-β and VEGF [189–191].